Predictors of oral anticoagulant-associated adverse events in seniors transitioning from hospital to home: a retrospective cohort study protocol

Harsukh Benipal, Anne Holbrook, J Michael Paterson, James Douketis, Gary Foster, Lehana Thabane, Harsukh Benipal, Anne Holbrook, J Michael Paterson, James Douketis, Gary Foster, Lehana Thabane

Abstract

Introduction: Oral anticoagulants (OACs) are widely prescribed in older adults. High OAC-related adverse event rates in the early period following hospital discharge argue for an analysis to identify predictors. Our objective is to identify and validate clinical and continuity of care variables among seniors discharged from hospital on an OAC, which are independently associated with OAC-related adverse events within 30 days.

Methods and analysis: We propose a population-based retrospective cohort study of all adults aged 66 years or older who were discharged from hospital on an OAC from September 2010 to March 2015 in Ontario, Canada. The primary outcome is a composite of the first hospitalisation or emergency department visit for a haemorrhage or thromboembolic event or mortality within 30 days of hospital discharge. A Cox proportional hazards model will be used to determine the association between the composite outcome and a set of prespecified covariates. A split sample method will be adopted to validate the variables associated with OAC-related adverse events.

Ethics and dissemination: The use of data in this project was authorised under section 45 of Ontario's Personal Health Information Protection Act, which does not require review by a research ethics board. Results will be disseminated via peer-reviewed publications and presentations at conferences and will determine intervention targets to improve OAC management in upcoming randomised trials.

Trial registration number: ClinicalTrials.gov Identifier: NCT02777047; Pre-results.

Keywords: anticoagulation; clinical pharmacology; epidemiology; protocols & guidelines; statistics & research methods.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. GYH L, Banerjee A, Boriani G, et al. . Antithrombotic therapy for atrial fibrillation. Chest 2018;154:1121–201.
    1. Kearon C, Akl EA, Ornelas J, et al. . Antithrombotic therapy for VTe disease. Chest 2016;149:315–52. 10.1016/j.chest.2015.11.026
    1. Steffel J, Verhamme P, Potpara TS, et al. . The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018;39:1330–93. 10.1093/eurheartj/ehy136
    1. Witt DM, Nieuwlaat R, Clark NP, et al. . American Society of hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv 2018;2:3257–91. 10.1182/bloodadvances.2018024893
    1. Institute for Safe Medication Practices ISMP list of high-alert medications in acute care settings, 2014. Available: [Accessed 25 May 2019].
    1. Shehab N, Lovegrove MC, Geller AI, et al. . Us emergency department visits for outpatient adverse drug events, 2013-2014. JAMA 2016;316:2115–25. 10.1001/jama.2016.16201
    1. Canadian Institute for Health Information Adverse drug Reaction–Related hospitalizations among seniors, 2006 to 2011. Ottawa, 2013. Available:
    1. Holbrook A, Paterson M, Martins D, et al. . Patient transitions and oral anticoagulant safety: a population-based cohort. Can J Cardiol 2018;34:S27–8. 10.1016/j.cjca.2018.07.367
    1. Chen LM, Ayanian JZ. Care continuity and care coordination: what counts? JAMA Intern Med 2014;174:749. 10.1001/jamainternmed.2013.14331
    1. (CIHI) CI for HI Physician follow-up after hospital discharge: progress in meeting best practices. Available: [Accessed 17 May 2019].
    1. World Health Organization Continuity and coordination of care: a practical brief to support implemntation of the who framework on integrated people-centred health services. Geneva, 2018.
    1. Misky GJ, Wald HL, Coleman EA. Post-hospitalization transitions: examining the effects of timing of primary care provider follow-up. J Hosp Med 2010;5:392–7. 10.1002/jhm.666
    1. Lin CY, Barnato AE, Degenholtz HB. Physician follow-up visits after acute care hospitalization for elderly Medicare beneficiaries discharged to noninstitutional settings. J Am Geriatr Soc 2011;59:1947–54. 10.1111/j.1532-5415.2011.03572.x
    1. Shen E, Koyama SY, Huynh DN, et al. . Association of a dedicated Post-Hospital discharge follow-up visit and 30-day readmission risk in a Medicare advantage population. JAMA Intern Med 2017;177:132. 10.1001/jamainternmed.2016.7061
    1. Hernandez AF, Greiner MA, Fonarow GC, et al. . Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA 2010;303:1716–22. 10.1001/jama.2010.533
    1. Sharma G, Kuo Y-F, Freeman JL, et al. . Outpatient follow-up visit and 30-day emergency department visit and readmission in patients hospitalized for chronic obstructive pulmonary disease. Arch Intern Med 2010;170:1664–70. 10.1001/archinternmed.2010.345
    1. Delgado Guay MO, Guay MOD, Tanzi S, et al. . Characteristics and outcomes of advanced cancer patients who miss outpatient supportive care consult appointments. Support Care Cancer 2014;22:2869–74. 10.1007/s00520-014-2254-8
    1. Tung Y-C, Chang G-M, Chang H-Y, et al. . Relationship between early physician follow-up and 30-day readmission after acute myocardial infarction and heart failure. PLoS One 2017;12:e0170061. 10.1371/journal.pone.0170061
    1. Howlett JG, McKelvie RS, Costigan J, et al. . The 2010 Canadian cardiovascular Society guidelines for the diagnosis and management of heart failure update: heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs. Can J Cardiol 2010;26:185–202. 10.1016/S0828-282X(10)70367-6
    1. Albert NM, Barnason S, Deswal A, et al. . Transitions of care in heart failure. Circulation 2015;8:384–409. 10.1161/HHF.0000000000000006
    1. Halasyamani L, Kripalani S, Coleman E, et al. . Transition of care for hospitalized elderly patients--development of a discharge checklist for hospitalists. J Hosp Med 2006;1:354–60. 10.1002/jhm.129
    1. American College of Cardiology Hospital to home. Available: [Accessed 25 May 2019].
    1. Health Quality Ontario Health Quality Ontario. Quality Monitor: 2010 Report on Ontario’s Health System. Toronto, 2010. Available:
    1. Health PEI Chronic obstructive pulmonary disease clinical pathway. Cbarlottetown, 2011. Available:
    1. Donaldson LJ, Kelley ET, Dhingra-Kumar N, et al. . Medication without harm: who's third global patient safety challenge. Lancet 2017;389:1680–1. 10.1016/S0140-6736(17)31047-4
    1. Aitken M, Gorokhovich L. Advancing the responsible use of medicines: applying levers for change. SSRN Journal 2012. 10.2139/ssrn.2222541
    1. Institute of Medicine Preventing medication errors. Washington: The National Academic Press, 2007.
    1. Feigenbaum P, Neuwirth E, Trowbridge L, et al. . Factors contributing to all-cause 30-day readmissions. Med Care 2012;50:599–605. 10.1097/MLR.0b013e318249ce72
    1. Suissa S, Garbe E. Primer: administrative health databases in observational studies of drug effects--advantages and disadvantages. Nat Clin Pract Rheumatol 2007;3:725–32. 10.1038/ncprheum0652
    1. Hashimoto RE, Brodt ED, Skelly AC, et al. . Administrative database studies: goldmine or goose Chase? Evid Based Spine Care J 2014;5:74–6. 10.1055/s-0034-1390027
    1. Statistics Canada Population estimates on July 1st, by age and sex, 2018. Available: [Accessed 25 May 2019].
    1. Schultz SE, Rothwell DM, Chen Z, et al. . Identifying cases of congestive heart failure from administrative data: a validation study using primary care patient records. Chronic Dis Inj Can 2013;33:160–6.
    1. Jaakkimainen RL, Bronskill SE, Tierney MC, et al. . Identification of Physician-Diagnosed Alzheimer’s Disease and Related Dementias in Population-Based Administrative Data: A Validation Study Using Family Physicians’ Electronic Medical Records. JAD 2016;54:337–49. 10.3233/JAD-160105
    1. Hux JE, Ivis F, Flintoft V, et al. . Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 2002;25:512–6. 10.2337/diacare.25.3.512
    1. Tu K, Chen Z, Lipscombe LL, et al. . Prevalence and incidence of hypertension from 1995 to 2005: a population-based study. CMAJ 2008;178:1429–35. 10.1503/cmaj.071283
    1. Tu K, Campbell NR, Chen Z-L, et al. . Accuracy of administrative databases in identifying patients with hypertension. Open Med 2007;1:e18–26.
    1. Wells G, Coyle D, Cameron C, et al. . Safety, effectiveness, and cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Canadian Agency for Drugs and Technologies in Health 2012.
    1. van der Linden CMJ, Jansen PAF, van Geerenstein EV, der LCMJvan, van GEV, et al. . Reasons for discontinuation of medication during hospitalization and documentation thereof: a descriptive study of 400 geriatric and internal medicine patients. Arch Intern Med 2010;170:1085-7. 10.1001/archinternmed.2010.159
    1. Viktil KK, Blix HS, Eek AK, et al. . How are drug regimen changes during hospitalisation handled after discharge: a cohort study. BMJ Open 2012;2:e001461. 10.1136/bmjopen-2012-001461
    1. Little D, Chai-Adisaksopha C, Hillis C, et al. . Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding: a systematic review and meta-analysis. Thromb Res 2019;175:102–9. 10.1016/j.thromres.2019.01.020
    1. Levy AR, O'Brien BJ, Sellors C, et al. . Coding accuracy of administrative drug claims in the Ontario drug benefit database. Can J Clin Pharmacol 2003;10:67–71.
    1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–51. 10.1056/NEJMoa0905561
    1. Patel MR, Mahaffey KW, Garg J, et al. . Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–91. 10.1056/NEJMoa1009638
    1. Granger CB, Alexander JH, McMurray JJV, et al. . Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–92. 10.1056/NEJMoa1107039
    1. Varadhan R, Weiss CO, Segal JB, et al. . Evaluating health outcomes in the presence of competing risks. Med Care 2010;48:S96–105. 10.1097/MLR.0b013e3181d99107
    1. Andersen PK, Geskus RB, de Witte T, et al. . Competing risks in epidemiology: possibilities and pitfalls. Int J Epidemiol 2012;41:861–70. 10.1093/ije/dyr213
    1. Tamariz L, Harkins T, Nair V. A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data. Pharmacoepidemiol Drug Saf 2012;21 Suppl 1:154–62. 10.1002/pds.2341
    1. Sanfilippo KM, Wang T-F, Gage BF, et al. . Improving accuracy of international classification of diseases codes for venous thromboembolism in administrative data. Thromb Res 2015;135:616–20. 10.1016/j.thromres.2015.01.012
    1. Arnason T, Wells PS, van Walraven C, et al. . Accuracy of coding for possible warfarin complications in hospital discharge Abstracts. Thromb Res 2006;118:253–62. 10.1016/j.thromres.2005.06.015
    1. White RH, Garcia M, Sadeghi B, et al. . Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States. Thromb Res 2010;126:61–7. 10.1016/j.thromres.2010.03.009
    1. Birman-Deych E, Waterman AD, Yan Y, et al. . Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care 2005;43:480–5. 10.1097/01.mlr.0000160417.39497.a9
    1. Juurlink D, Preyra C, Croxford R, et al. . Canadian Institute for health information discharge Abstract database: a validation study. Toronto, 2006. Available: [Accessed 28 May 2019].
    1. Quan H, Li B, Saunders LD, et al. . Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database. Health Serv Res 2008;43:1424–41. 10.1111/j.1475-6773.2007.00822.x
    1. Tanuseputro P, Budhwani S, Bai YQ, et al. . Palliative care delivery across health sectors: a population-level observational study. Palliat Med 2017;31:247–57. 10.1177/0269216316653524
    1. Steinberg BA, Greiner MA, Hammill BG, et al. . Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation. Cardiovasc Ther 2015;33:177–83. 10.1111/1755-5922.12129
    1. Decousus H, Tapson VF, Bergmann J-F, et al. . Factors at admission associated with bleeding risk in medical patients. Chest 2011;139:69–79. 10.1378/chest.09-3081
    1. Schünemann HJ, Cushman M, Burnett AE, et al. . American Society of hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv 2018;2:3198–225. 10.1182/bloodadvances.2018022954
    1. MHASEF Research Team Mental health and addictions system performance in Ontario: a baseline Scorecard. Toronto, 2018.
    1. Quan H, Li B, Couris CM, et al. . Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge Abstracts using data from 6 countries. Am J Epidemiol 2011;173:676–82. 10.1093/aje/kwq433
    1. Pisters R, Lane DA, Nieuwlaat R, et al. . A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro heart survey. Chest 2010;138:1093–100. 10.1378/chest.10-0134
    1. Olesen JB, Lip GYH, Hansen ML, et al. . Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011;342:d124. 10.1136/bmj.d124
    1. Douketis JD, Spyropoulos AC, Spencer FA, et al. . Perioperative management of antithrombotic therapy. Chest 2012;141:e326S–50. 10.1378/chest.11-2298
    1. Adam SS, McDuffie JR, Ortel TL, et al. . Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med 2012;157:796. 10.7326/0003-4819-157-10-201211200-00532
    1. Hinojar R, Jiménez-Natcher JJ, Fernández-Golfín C, et al. . New oral anticoagulants: a practical guide for physicians. Eur Heart J Cardiovasc Pharmacother 2015;1:134–45. 10.1093/ehjcvp/pvv002
    1. Vranckx P, Valgimigli M, Heidbuchel H. The significance of drug-drug and Drug-Food interactions of oral anticoagulation. Arrhythm Electrophysiol Rev 2018;7:55–61. 10.15420/aer.2017.50.1
    1. Sayani S, Iqbal O, Hoppensteadt D, et al. . Drug interactions of newer oral anticoagulants dabigatran, rivaroxaban, and apixaban with routinely used Nonanticoagulant/Antiplatelet drugs. Blood 2014;124:4267 10.1182/blood.V124.21.4267.4267
    1. Liu A, Abrahamowicz M, Siemiatycki J. Conditions for confounding of interactions. Pharmacoepidemiol Drug Saf 2016;25:287–96. 10.1002/pds.3924
    1. Health Quality Ontario Quality in primary care: setting a foundation for monitoring and reporting in Ontario. Toronto, 2015.
    1. Lapointe-Shaw L, Mamdani M, Luo J, et al. . Effectiveness of a financial incentive to physicians for timely follow-up after hospital discharge: a population-based time series analysis. CMAJ 2017;189:E1224–9. 10.1503/cmaj.170092
    1. van Walraven C, Mamdani M, Fang J, et al. . Continuity of care and patient outcomes after hospital discharge. J Gen Intern Med 2004;19:624–31. 10.1111/j.1525-1497.2004.30082.x
    1. Williams JI, Young W. A Summary of Studies on the Quality of Health Care Administrative Databases in Canada : Goel V, Williams JI, Anderson GM, et al., Patterns of health care in Ontario, the ICES practice atlas. 2nd edn Ottawa: Canadian Medical Association, 1996: 339–45.
    1. Kyriacou DN, Lewis RJ. Confounding by indication in clinical research. JAMA 2016;316:1818–9. 10.1001/jama.2016.16435
    1. Csizmadi I, Collet J-P, Boivin J-F. Bias and confounding in pharmacoepidemiology. in: pharmacoepidemiology. Chichester, UK: John Wiley & Sons, Ltd, 2006: 791–809.
    1. Austin PC, Mamdani MM, van Walraven C, et al. . Quantifying the impact of survivor treatment bias in observational studies. J Eval Clin Pract 2006;12:601–12. 10.1111/j.1365-2753.2005.00624.x
    1. Ogundimu EO, Altman DG, Collins GS. Adequate sample size for developing prediction models is not simply related to events per variable. J Clin Epidemiol 2016;76:175–82. 10.1016/j.jclinepi.2016.02.031
    1. Faraway JJ. Does data splitting improve prediction? Stat Comput 2016;26:49–60. 10.1007/s11222-014-9522-9
    1. Picard RR, Berk KN. Data splitting. Am Stat 1990;44:140.
    1. Royston P, Moons KGM, Altman DG, et al. . Prognosis and prognostic research: developing a prognostic model. BMJ 2009;338:b604. 10.1136/bmj.b604
    1. Derksen S, Keselman HJ, Backward KHJ. Backward, forward and stepwise automated subset selection algorithms: frequency of obtaining authentic and noise variables. Br J Math Stat Psychol 1992;45:265–82. 10.1111/j.2044-8317.1992.tb00992.x
    1. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361–87. 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>;2-4
    1. Uchino K, Hernandez A. Dabigatran association with higher risk of acute coronary events. Arch Intern Med 2012;172:397 10.1001/archinternmed.2011.1666
    1. Clemens A, Fraessdorf M, Friedman J. Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. Vasc Health Risk Manag 2013;9:599–615. 10.2147/VHRM.S49830
    1. Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation 2016;133:601–9. 10.1161/CIRCULATIONAHA.115.017719

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa